JP Morgan Chase
ECYT

JP Morgan Chase’s Endocyte, Inc. Common Stock ECYT Stock Holding History

JP Morgan Chase’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-142,854
Closed -$2.54M – 6092
2018
Q3 		$2.54M Buy
142,854
+129,556
+974% +$2.22M ﹤0.01% 3296
2018
Q2 		$183K Buy
+13,298
New +$158K ﹤0.01% 4595
2017
Q4 		– Sell
-53,778
Closed -$73K – 5686
2017
Q3 		$73K Sell
53,778
-188,688
-78% -$263K ﹤0.01% 4384
2017
Q2 		$364K Sell
242,466
-368,577
-60% -$791K ﹤0.01% 3835
2017
Q1 		$1.57M Sell
611,043
-178,692
-23% -$413K ﹤0.01% 3175
2016
Q4 		$2.01M Buy
789,735
+68,060
+9% +$195K ﹤0.01% 3068
2016
Q3 		$2.23M Sell
721,675
-60,810
-8% -$190K ﹤0.01% 2733
2016
Q2 		$2.51M Buy
782,485
+779,900
+30,170% +$2.86M ﹤0.01% 2689
2016
Q1 		$8K Buy
+2,585
New +$8.44K ﹤0.01% 4298
2013
Q4 		– Sell
-23,245
Closed -$310K – 4345
2013
Q3 		$310K Sell
23,245
-10,400
-31% -$164K ﹤0.01% 3860
2013
Q2 		$442K Buy
+33,645
New +$454K ﹤0.01% 3657

Other funds holding ECYT

OTC
Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return
CA
Claro Advisors Boston, Massachusetts $953M AUM 24.79% 1-Year Est. Return

JP Morgan Chase's ECYT Position: Q4 2018 in Review

JP Morgan Chase sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 142,854 shares — an estimated $2.54M sold.

JP Morgan Chase first reported a position in ECYT in Q2 2013 and held it in 11 quarters. The position peaked at $2.54M in Q3 2018. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.

  • JP Morgan Chase reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • JP Morgan Chase sold 142,854 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $2.54M.
  • JP Morgan Chase first reported a position in Endocyte, Inc. Common Stock in Q2 2013 and held it in 11 quarters.
  • JP Morgan Chase's Endocyte, Inc. Common Stock position peaked at $2.54M in Q3 2018.
  • 2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.

Based on JP Morgan Chase's 13F filing for Q4 2018, filed 11 Feb 2019.